Search Results
Mar 24, 2026, 22:40 ET Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug conjugate (ADC), and AK138D1, an innovative HER3-targeting ADC. The studies will evaluate these two novel ADC candidates in combination with the Company's pioneering immuno-oncology (IO) 2.0 bispecific antibodies,
More news about: Akeso, Inc.
Mar 24, 2026, 13:38 ET 科倫博泰公佈2025年業績：多款產品成功上市，階梯式研發管線蓄勢待發
2期臨床階段SKB315 (CLDN18.2 ADC)：SKB315的1b期臨床試驗正在進行中，用於治療胃癌/胃食管結合部癌/胰腺導管腺癌等。SKB315治療包括胃癌/胃食管結合部癌在內的晚期實體瘤患者的1期研究結果於2025年10月在2025年ESMO大會上發布。SKB410/MK-3120 (Nectin-4 ADC)：合作夥伴默沙東(MSD)已啟動了4項SKB410/MK-3120靶向膀胱癌等晚期實體瘤的全球1/2期臨床試驗。
More news about: 科倫博泰
Mar 24, 2026, 10:47 ET Fosun Pharma Announces 2025 Annual Results
becoming the first anti-PD-1 monoclonal antibody to receive such approval in the EU and accelerating the company's globalization pace; antibody and ADC drugs such as HLX43 and HLX22 entered key clinical phases, continuously improving the echelon of the oncology pipeline. The marketing application for
More news about: Fosun Pharma
Mar 24, 2026, 07:57 ET RYBODYN ANNOUNCES SEED FINANCING TO ADVANCE AI-DRIVEN DISCOVERY OF HIDDEN CANCER TARGETS
allows us to identify entirely new, actionable targets."The company has already demonstrated proof-of-concept in vitro, including the first-ever ADC-mediated killing of tumor cells via a cryptic protein target—a milestone that helped catalyze the current financing. "RyboDyn is tackling one of the
More news about: RyboDyn
Mar 24, 2026, 05:02 ET Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC
As one of the industry leaders in the ADC field, Kelun-Biotech has established a solid competitive advantage. Currently, the Company's self-developed TROP2 ADC and HER2 ADC have been approved for marketing, demonstrating significant clinical efficacy and competitive
More news about: Kelun-Biotech
Mar 24, 2026, 04:49 ET 科倫博泰首個TAA-PD-L1雙抗ADC藥物SKB103獲批臨床，新型偶聯藥物戰略加速落地
作為ADC領域的行業領軍者之一，科倫博泰已建立起堅實的領先優勢。目前，公司自主研發的TROP2 ADC、HER2 ADC均已獲批上市，並展現顯著的臨床療效及差異化的競爭優勢。與此同時，公司著眼於腫瘤治療的迭代升級，持續拓展創新佈局，構建了涵蓋RDC、雙抗ADC等前沿療法的多元化管線矩陣，全力推動腫瘤現有治療模式的突破與革新。SKB103是公司基於專有的OptiDC™平台研發的一款潛在
More news about: 科倫博泰
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
R&D technology platforms.Exploration of IO2.0+ADC Combination TherapiesNext-generation IO+ADC combination therapy is a core development trend in the global biopharmaceutical industry. The "bispecific antibody + ADC" combination can not only improve the efficacy of indications
More news about: Duality Biotherapeutics, Inc.
Mar 24, 2026, 02:20 ET 映恩生物（9606.HK）公佈2025年度業績
映恩生物創始人、董事長兼首席執行官朱忠遠博士表示：「過去十年，創新藥行業經歷了從局部探索到體系化發展的階段。今天，我們正站在一個新的起點上——一個更開放、更不確定、也更具想像力的創新藥時代。技術的演進正在重塑邊界，全球臨床與監管體系逐步打通，創新不再局限於某一個地區，而是在全球範圍內協同發生。2025 年，映恩生物以創新為錨，在 ADC 賽道踏浪而行。我們憑藉四大核心技術平臺的深厚積澱，推動核心資產全速進階：3200 余名全球患者的入組，見證了我們的研發硬實力與全球佈局初心。與 BioNTech、Avenzo 等夥伴的深度協作，更讓創新價值持續放大，為長遠發展注入強勁動能。2026 年，我們將乘勢而上，加速核心產品商業化落地，深耕管線反覆運算與技術突破，穩步推進
More news about: Duality Biotherapeutics, Inc.
Mar 23, 2026, 22:31 ET KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
Company has also successfully established its internationally renowned proprietary ADC and novel conjugated drug platform, OptiDCTM, with 2 ADC projects covering 5 indications approved for market launch, and several ADC or novel conjugated drug projects in clinical or preclinical development.
More news about: Kelun-biotech
Mar 23, 2026, 09:15 ET WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
growthWinner of "Best CDMO" and "Best CRO" Awards: Three consecutive "Best CDMO" Awards from 2023 to 2025 at World ADC Awards, and "Best CRO" Awards at 2025 World ADC AwardsSHANGHAI, March 23, 2026 /PRNewswire/
More news about: WuXi XDC
Mar 23, 2026, 08:34 ET GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC
collaboration will center on research and development activities for GNX201-ADC including optimization of the ADC construct and generation of preclinical data to support regulatory submissions. GNX201-ADC is designed as a protease-activated ADC that remains stable in circulation and is selectively activated in
More news about: GlycoNex, Inc.
Mar 22, 2026, 23:14 ET Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage.About Windward Bio
More news about: Harbour BioMed
Mar 22, 2026, 22:20 ET Henlius informa sus resultados de 2025: Crecimiento sostenido tanto en ingresos como en beneficios
Henlius continúa impulsando su cartera de productos innovadores, con activos clave como dulpatatug (HLX22, un nuevo epítopo anti-HER2 mAb) y HLX43 (PD-L1 ADC) que se encuentran en fases clínicas críticas.Gracias a sus capacidades integradas que abarcan I+D, operaciones clínicas, regulación, fabricación
More news about: Henlius
Mar 22, 2026, 22:18 ET Henlius présente ses résultats pour 2025 : croissance soutenue du chiffre d'affaires et du bénéfice, progression de la validation de l'innovation et des opérations mondiales
continue de faire progresser son pipeline d'innovations, avec des actifs clés tels que dulpatatug (HLX22, nouvel épitope anti-HER2 mAb) et HLX43 (PD-L1 ADC) qui entrent dans des phases cliniques critiques.Grâce à ses capacités intégrées en matière de R&D, d'opérations cliniques, de réglementation,
More news about: Henlius
Mar 22, 2026, 22:14 ET Henlius gibt Ergebnisse für 2025 bekannt: Anhaltendes Wachstum bei Umsatz und Gewinn, Ausbau der Innovationsvalidierung und der weltweiten Geschäftstätigkeit
gleichzeitig seine Innovationspipeline weiter voran und wichtige Wirkstoffe wie Dulpatatug (HLX22, ein neuartiger Epitop-Anti-HER2-mAb) und HLX43 (PD-L1-ADC) treten nun in entscheidende klinische Phasen ein.Gestützt auf seine integrierten Kompetenzen in den Bereichen Forschung und Entwicklung, klinische
More news about: Henlius
Mar 20, 2026, 14:56 ET First Industrial Realty Trust Comments on Land & Buildings' Withdrawal of Jonathan Litt as a Director Nominee
Note: Proxy peers based on flat average of ADC, BRX, COLD, CUBE, EGP, HR, KRG, LXP, MAC, OHI, REXR, STAG and TRNO; Industrial peers based on flat average of PLD, REXR, EGP and TRNOAbout
More news about: First Industrial Realty Trust, Inc.
Mar 20, 2026, 09:23 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
Meanwhile, Henlius continues to advance its innovation pipeline, with key assets including dulpatatug (HLX22, novel epitope anti-HER2 mAb) and HLX43 (PD-L1 ADC) entering critical clinical stages.Supported by its integrated capabilities spanning R&D, clinical operations, regulatory, manufacturing,
More news about: Henlius
Mar 20, 2026, 09:03 ET 復宏漢霖2025年業績：收入利潤持續雙增長，體系出海加速落地，創新管線進入密集驗證期
®），成為美國首款且唯一[1]的帕妥珠單抗生物類似藥，並在歐盟獲得EMA上市許可積極意見，以及在中國及加拿大遞交上市申請。公司持續打造更完善的乳腺癌創新產品矩陣，新型內分泌療法、新表位抗HER2單抗、HER2 ADC、KAT6A/B口服小分子抑制劑、HER2雙表位ADC、LIV-1 ADC等正在加速佈局。公司成熟商業化品種亦持續貢獻穩定現金流。漢貝泰®（貝伐珠單抗）實現銷售收入3.564億元，同比增長80.8%。基於與合作夥伴的約定
More news about: 復宏漢霖
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
portfolio, including novel endocrine therapy, novel epitope anti-HER2 mAb, HER2-targeted ADC, KAT6A/B oral small-molecule inhibitor, subcutaneous formulation of pertuzumab and trastuzumab, dual-epitope HER2 ADC, and LIV-1 ADC.Meanwhile, mature commercialized products continued to generate stable cash
More news about: Henlius
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
Other Novel Programs ATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an "IO + ADC" dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of IO therapies. By simultaneously blocking B7-H3-
More news about: Antengene Corporation Limited
Mar 18, 2026, 20:00 ET SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
- Safety & efficacy of iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based antibody-drug conjugate (ADC) in combination with serplulimab (an anti-PD1 antibody), in treatment-naive patients with Extensive stage Small Cell Lung Cancer (ES-SCLC) will be presented
More news about: SystImmune, Inc.
Mar 18, 2026, 10:27 ET Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Mar 18, 2026, 06:00 ET IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
potential first-in-class programs from IDEAYA's clinical stage pipeline: IDE034, a PTK7/B7H3 bi-specific topoisomerase-1 (TOP1) antibody-drug conjugate (ADC); IDE574, a potent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7; and IDE892, an MTA-cooperative inhibitor of PRMT5. The company is currently
More news about: IDEAYA Biosciences, Inc.
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
Convention Center, California, the United States. The presentations will feature ATG-125 (B7-H3 x PD-L1 bispecific antibody-drug conjugate [ADC]), an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers (TCEs) developed using
More news about: Antengene Corporation Limited
Mar 17, 2026, 16:30 ET Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
preclinical proof-of-concept for our three ADC programs, HWK-007, HWK-016 and HWK-206," said David Dornan, PhD, Chief Scientific Officer of Whitehawk Therapeutics. "These data will highlight the optimized ADC design features aimed at delivering a differentiated ADC profile with the goal of improving outcomes
More news about: Whitehawk Therapeutics, Inc.